Transforming Rare-Disease Research Through Applied Intelligence
Explore how AnnieGuard’s Biological-First Intelligence is redefining precision medicine, improving trial diversity, and accelerating early detection across rare diseases.
Advanced Analytics for Clinical Trial Diversity — Soft-Tissue Sarcoma
AnnieGuard’s quantum-enhanced analytics uncovered hidden biological-demographic patterns across 422 sarcoma patients, identifying 68 underrepresented candidates eligible for active biomarker-matched trials—proving equity and efficacy can coexist.
Key Metrics:
-
+13.4 pp increase in minority enrollment
-
33% reduction in disparity
-
8% gain in genomic coverage
-
17% improvement in survival balance
Identifying Responder Populations in a Discontinued Glioblastoma Program
After a glioblastoma trial showed no overall benefit, the experimental integrin inhibitor program was discontinued. But was that the end of the story?
AnnieGuard's reanalysis of the clinical trial data (n=83) revealed something traditional population averaging missed: 11% of patients achieved nearly double the median survival of the overall cohort (23.8 vs. 13.6 months). These patients shared a distinct biological profile invisible to conventional statistical methods. The pattern suggests that baseline biology—not just tumor genetics—determines who responds to integrin inhibition. Patients with low inflammatory burden maintained the biological conditions necessary for drug efficacy and tolerance.
What Made Them Different?
The high-performing subgroup had:
-
Lower baseline inflammation (34% lower neutrophil counts)
-
Better metabolic reserves (5% higher albumin levels)
-
Markedly better tolerability (78% fewer severe adverse events)
Foundational Validation: The Original SarcRisk™ Model for Early Sarcoma Detection (Pre-Expansion Study)
This open-access research paper documents the first generation of AnnieGuard’s SarcRisk™ model, developed to identify soft-tissue sarcoma from public clinical–genomic data.
While this early-stage version used a smaller dataset, it provided the first validation that AI and advanced statistics could detect sarcoma-specific biological signatures before clinical diagnosis — laying the groundwork for AnnieGuard’s current large-scale, precision-grade models.
(Published in Sarcoma Research – International, 2025; open-access archival publication)
This paper represents the earliest iteration of AnnieGuard’s SarcRisk™ engine. The platform has since been re-engineered using thousands of patient records, multi-cohort validation, and expanded molecular data to power our current precision-detection suite.
Key Metrics (Original Prototype):
-
100% Specificity — zero false positives across 300 non-sarcoma controls
-
78.9% Accuracy — reliable cross-stage performance
-
Stage-Spanning Detection — early- to late-stage sensitivity (38–51%)
-
Feasibility Established — demonstrated the possibility of algorithmic early detection in rare cancers